Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2013
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Milnacipran for Lumbosacral Radicular Pain
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 29, 2013
Lead Product(s) : Milnacipran
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Milnacipran for Chronic Pain in Knee Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2012
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : CYPRESS BIOSCIENCE
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : CYPRESS BIOSCIENCE
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 05, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : CYPRESS BIOSCIENCE
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : CYPRESS BIOSCIENCE
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Milnacipran
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Savella in Treatment for Provoked Vestibulodynia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 25, 2011
Lead Product(s) : Milnacipran
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Forest Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable